Enterococci Acquire New Kinds of Resistance
|
|
- Hubert Gilbert
- 6 years ago
- Views:
Transcription
1 S80 Enterococci Acquire New Kinds of Resistance Roland Leclercq From the Service de Bacteriologie-Virologie-Hygiene, HOpital Henri Mondor, Universite Paris XII, Creteil, France In recent years, enterococci have become increasingly resistant to a broad range of antimicrobial agents. The development of high-level resistance to aminoglycosides, penicillins, and glycopeptides singly and in combination has important clinical implications. Strains of Enterococcus faecium that are resistant to every useful available antibiotic have been described. Resistance to penicillin can be due to overproduction of penicillin-binding protein (which has low affinity for penicillins) or to production of 13-lactamase. High-level resistance of enterococci to gentamicin is due to the synthesis of a modifying enzyme. In this case, the synergistic activity of the combination of penicillin with any aminoglycoside (except for streptomycin) is totally abolished. Acquired resistance to glycopeptides is often plasmid-mediated and is associated with a major epidemic potential since certain plasmids are self-transferable from E. faecium to a variety of gram-positive organisms, including Staphylococcus aureus. Historically, enterococci have been considered rather feeble pathogens. However, this optimistic view is being challenged by the increasing number of nosocomial infections caused by these organisms [1]. Moreover, in recent years, enterococci have become increasingly resistant to a broad range of antimicrobial agents. For these reasons, increased attention has been focused on the enterococcus by the scientific and medical community [2]. The increase in incidence of nosocomial infections caused by enterococci in particular, Enterococcus faecium is at least partly due to the wide variety of intrinsic and acquired resistances characteristic of these species. Consequently, enterococci are well suited to survive in hospital settings, where antibiotic selective pressure is heavy. The development of highlevel resistance to aminoglycosides, penicillins, and glycopeptides (vancomycin and teicoplanin) singly and in combination has important clinical implications. In this article the described major mechanisms of antimicrobial resistance in enterococci are reviewed. Intrinsic Resistance in Enterococci The limited choice of antibiotics and the poor results of single-agent antimicrobial therapy in the treatment of serious enterococcal infections are mostly related to the intrinsic resistance of the organism. Intrinsic resistance is an inherent property of a bacterial genus or species. Enterococci are intrinsically resistant to 0-lactam antibiotics, aminoglycosides, and sulfonamides. Additional intrinsic resistance traits are characteristic of specific enterococcal species. Reprints or correspondence: Dr. R. Leclercq, Service de Bacteriologie-Virologie-Hygiêne, HOpital Henri Mondor, University Paris XII, 51, Avenue Marechal de Lattre de Tassigny, Crêteil Cedex, France. Clinical Infectious Diseases 1997; 24(Suppl 1):S by The University of Chicago. All rights reserved /97/ $ lactam agents and aminoglycosides. The MICs of penicillin G, ampicillin, amoxicillin, piperacillin, and imipenem against enterococci are times greater than those against streptococci. The increased resistance of enterococci has been associated with the presence of penicillin-binding proteins (PBPs) with decreased affinity for /3-lactams [3, 4]. In addition, even 0-lactam agents that have activity are not bactericidal against the majority of strains. Poor bactericidal activity is also observed with other cell-wall-active agents such as glycopeptides. Resistance to cephalosporins is still more pronounced and renders these drugs ineffective in vivo. Combinations of 0-lactams or glycopeptides with aminoglycosides achieve bactericidal synergy, although the MICs of the aminoglycosides generally range from 8 mg/l to 64 mg/l. This low-level resistance to aminoglycosides is also an intrinsic property of enterococci. Since aminoglycoside uptake by bacteria requires oxidatively generated energy [5], intrinsic resistance probably reflects inefficient active transport of aminoglycoside due to poor membrane energization. The mechanism by which a cell-wall-synthesis inhibitor/aminoglycoside combination achieves synergy is explained by the facilitation of aminoglycoside uptake that results from disruption of the cell wall by the cell-wall-active agent [6]. Sulfonamides and trimethoprim. When tested in vitro in appropriate conditions i.e., in media devoided of thymidine, which reverses the action of co-trimoxazole enterococci appear susceptible to this antibiotic combination. However, under certain circumstances, enterococci can use exogenous folates, present in the urine, for instance. They could thereby escape inhibition by antifolate agents and could be resistant in vivo to these antimicrobials. This point is controversial since it has been demonstrated for E. faecium but not clearly for Enterococcus faecalis [7]. However, co-trimoxazole was not efficacious in treatment of experimental endocarditis due to E. faecalis in a rabbit model [8]. Intrinsic resistance of specific enterococcal species. All strains of E. faecium produce an aminoglycoside 6'-acetyltrans-
2 CID 1997;24 (Suppl 1) Enterococcal Resistance to Antibiotics S81 ferase, encoded by the chromosomal gene aac(6')-ii, which modifies most commercially available aminoglycosides [9]. Production of this enzyme abolishes the bactericidal activity of a penicillin or a glycopeptide with an aminoglycoside, except with aminoglycosides that are not substrates for the enzyme, such as streptomycin and gentamicin. It is surprising that the synergy of amikacin combined with a penicillin is also retained, although this aminoglycoside is a substrate for the enzyme [10]. Vancomycin has low intrinsic activity (MIC, 2-32 mg/l) against some rarely isolated enterococcal species such as Enterococcus gallinarum, Enterococcus casseliflavus, and Enterococcus flavescens. The lower MIC breakpoint of vancomycin (4 mg/l) divides the bacterial population into two unequal parts, with certain isolates categorized as susceptible [11]. The glycopeptide resistance genes vanc] for E. gallinarum and vanc2 for E. casseliflavus and E. flavescens are specific for these species [12, 13]. Intrinsic resistance of E. faecalis to clindamycin is helpful in bacterial identification. E. faecalis is also resistant to streptogramin A type antibiotics [14]. Except for Enterococcus durans and E. faecium, most enterococcal species display both resistances. Acquired Resistance /3-Lactam antibiotics. Acquired resistance to 0-lactam antibiotics can be due to synthesis of /3-lactamase or to modification of the PBP target. Although both mechanisms can be present in E. faecalis and in E. faecium, they are not represented equally. /3-Lactamase-producing strains of E. faecalis were first isolated in 1981 in the United States and subsequently in Argentina and Lebanon [15]. Resistance due to such synthesis is rare in E. faecium. Resistance due to f3-lactamase production is generally plasmid-mediated and is often linked with highlevel resistance to gentamicin [15]. The /3-lactamase is a penicillinase that is highly homologous to that encoded by the blaz gene of Staphylococcus aureus [16]. However, unlike that of S. aureus, the penicillinase of E. faecalis is constitutively produced, possibly due to the absence of a repressor protein [17]. Although clonal spread of /3-lactamase-producing enterococci has been reported [18], for the most part this type of resistance remains confined to specific hospitals and does not account for the reported overall increase in resistance of enterococci to penicillin. This increase is mostly due to the spread of penicillinresistant E. faecium strains that do not produce /3-lactamase. Resistance in these strains is due to modification of PBPs, particularly overproduction of a preexisting PBP that has low affinity for /3-lactam drugs. This mechanism was first studied in Enterococcus hirae. In laboratory isolated mutants, the amount of low-affinity PBP5 correlated to the level of penicillin resistance; the MIC of penicillin was approximately equal to that of /3-lactam drug necessary to saturate PBP5 [19]. These strains grew normally in the presence of penicillin concentrations that saturated all PBPs, except PBP5, which suggests that when PBP5 is overproduced, it can substitute for the functions of all the other PBPs of the cell. Overproduction of this protein may be due to a deletion in an upstream regulatory region of the E. hirae PBP5 gene pbp5 [20]. It is interesting that the aminoacid sequence of E. hirae PBP5 is 33% homologous to PBP2a, which confers methicillin resistance in staphylococci [21]. Penicillin-resistant mutants can be readily selected in vitro among other enterococcal species, including E. faecalis [22]. However, penicillin-resistant clinical isolates of only a limited number of species have been reported, including E. faecium and, to a lesser extent, Enterococcus raffinosus. Clinical isolates of E. faecium display various levels of penicillin resistance, with MICs of penicillin ranging from 8 mg/l to >512 mg/l. Among moderately resistant strains of E. faecium, the mechanism of penicillin resistance is also attributed to overproduction of PBP5 of this species. Further modifications in the primary structure of PBP5, leading to additional decreases in penicillin-binding capacity, appear responsible for a high level of penicillin resistance [23]. Aminoglycosides. Enterococci acquire resistance to aminoglycosides by three distinct mechanisms: alteration of the ribosomal target site, interference with antibiotic transport, and enzymic detoxification of the antibiotic. The first two mechanisms are due to chromosomal mutations, whereas the third mechanism is generally mediated by plasmids [24]. In clinical enterococcal isolates, high-level resistance (MIC, >1,000 mg/l) is usually mediated by aminoglycoside-modifying enzymes. However, in certain strains of E. faecalis, high-level resistance to streptomycin can also be due to ribosomal mutations [25]. As is the case for gram-negative bacteria, the enzymes can be divided into any of three classes, depending upon the reaction catalyzed (phosphorylation or nucleotydilation of a hydroxyl group; acetylation of an amino group), and are named according to the site modified. The enzymes vary in their substrate ranges, which are often very broad. Identical aminoglycosidemodifying enzymes cause high-level resistance to aminoglycosides and/or resistance to synergism with penicillins in enterococci and staphylococci [26]. Numerous enzymes have been described, including streptomycin adenylyltransferase, 3 '-phosphotransferase, 4'-nucleotidyltransferase (rare in enterococci), and a bifunctional 6'-acetyltransferase 2" phosphotransferase (AAC[6']-APH[2"]). The latter enzyme is a fusion protein that has dual enzymic activity, conferring high-level resistance to gentamicin and to most commercially available aminoglycosides [27]. The presence of an enzyme confers to the host high-level resistance toward the antibiotics that are modified in vitro. As expected, the synergistic activity of the combination of a penicillin with an aminoglycoside is abolished. It is surprising that this suppression also occurs when the aminoglycoside is a poor substrate for the enzyme and when,
3 S82 Leclercq CID 1997;24 (Suppl 1) consequently, its bacteriostatic activity is not significantly affected. For instance, the rate of modification of amikacin and netilmicin by AAC(6')-APH(2") is not sufficient to confer highlevel resistance to the host (MICs, only between 64 mg/l and 256 mg/l) but can prevent the synergism between these antibiotics and penicillins or glycopeptides. In fact, synergism of the combination of penicillin with any aminoglycoside (except streptomycin) is suppressed [27]. A high incidence (>20%) of high-level gentamicin resistance in E. faecalis, including blood isolates, has been reported from various countries [28]. However, the incidence varies, depending on the particular hospital and ward. Glycopeptides. Acquired vancomycin resistance was first detected in 1986 [29, 30]. Two phenotypes, VANA and VANB, can be distinguished phenotypically on the basis of the antibacterial and inducing activity of glycopeptides. Inducible resistance to high levels of vancomycin (MIC, 64 mg/l) and teicoplanin (MIC, 16 mg/l) defines the VANA phenotype [30]. This class of resistance is usually mediated by self-transferable plasmids. VANB-type strains are inducibly resistant to various levels of vancomycin (MICs, 4 mg/l to 1,000 mg/l) and are susceptible to teicoplanin [31]. This dissociated phenotype is due to the fact that vancomycin acts as an inducer, whereas teicoplanin does not. Low- and high-level VANB-type resistance is transferable by conjugation in certain strains [31, 32]. Transfer of resistance is associated with mobilization of large genetic elements ( kb) from chromosome to chromosome [32]. Analyses of the nucleotide sequence of the resistance genes and of the functions of the corresponding proteins in the VANA-type strain E. faecium BM4147 have provided insights into the mechanism of resistance (for a review, see [33]). The resistance genes are carried by the 10.8-kb transposon named Tn1546 [34]. Tn1546 encodes nine polypeptides, two involved in transposition functions (ORF1 and ORFII) and seven cooperating to confer vancomycin resistance [33]. The seven polypeptides involved in the expression of VANA can be assigned to three functional groups: regulation of vancomycin resistance genes (VanR and VanS), resistance to glycopeptides by production of a modified target (VanH, VanA, and VanX), and accessory proteins that are not essential for the expression of glycopeptide resistance (VanY and VanZ). Glycopeptides are inhibitors of the cell-wall synthesis. They are large molecules that form complexes with the peptidyl-dalanyl-d-alanine termini of peptidoglycan precursors at the cell surface. The presence of these large complexes at the surface of the cytoplasmic membrane prevents cell-wall synthesis by hindering the transfer of cytoplasmic precursors to the growing peptidoglycan chain and by blocking formation of interpeptidic bonds [35]. The VanA and VanH proteins are a ligase of broad substrate specificity and a dehydrogenase, respectively, that act together to synthesize the depsipeptide D-alanyl-D-lactate, which replaces the D-alanyl-D-alanine terminus of peptidoglycan precursors [36]. Although the modified precursors can be incorporated normally into the cell wall by enzymes encoded by the host chromosome, the substitution results in a dramatic decrease in affinity for vancomycin. Hence, such strains are resistant, since vancomycin can no longer inhibit cell-wall synthesis. However, in addition to VanH and VanA, the VanX protein is also necessary for expression of glycopeptide resistance. VanX is a D,D dipeptidase that hydrolyzes the dipeptide D-alanyl-D-alanine, which should otherwise compete with D-alanyl-D-lactate [37]. The distal portion of Tn1546 encodes two proteins, VanY and VanZ, which are not required for glycopeptide resistance. VanY is a D,D carboxypeptidase that could contribute to resistance by cleaving the terminal D-alanine from precursors resulting from incorporation of D-alanyl-D-alanine that escape hydrolysis by VanX [38]. VanZ, which is not significantly related in structure to other proteins, appears to confer lowlevel resistance to teicoplanin by an unknown mechanism [39]. The vana, vanh and vanx resistance genes are regulated at the transcriptional level by the VanR-VanS two-component regulatory system, which is encoded upstream of vanh [40]. The two regulatory proteins are probably involved in transmitting a signal in response to the presence of vancomycin at the surface of the cell. Spread of VANA-type resistance in clinical isolates appears to be due to dissemination of Tn1546 or related elements in self-transferable plasmids rather than by spread of a bacterial clone or a single plasmid [34, 41]. Thus far, the van genes have been naturally detected only in enterococci. However, enterococci are known to be capable of exchanging gentamicin or macrolide resistance with other species of gram-positive organisms via transfer of conjugative plasmids [42]. Therefore, it is not surprising that some glycopeptide resistance plasmids have broad host ranges and can readily transfer in vitro to a variety of gram-positive organisms, including streptococci, Lactococcus lactis, Listeria monocytogenes, and (of most concern) S. aureus [41, 43]. In addition, VANA-type enterococci are widely spread in nature and have been isolated from the stools of healthy carriers, from farm animals, and from wastewater treatment plants [44]. These observations lead one to anticipate the future dissemination of glycopeptide resistance genes to more virulent pathogens. Multidrug Resistance Although the antibiotic resistances mentioned above can exist independently, they can be combined in a single strain and thus present more cause for concern. In particular, penicillin resistance due to overproduction of PBP5 or synthesis of 0- lactamase can be associated with glycopeptide resistance and high-level resistance to gentamicin. This accumulation of resistance traits has been observed mostly in E. faecium strains. The emergence of multidrug resistance also concerns alternative antimicrobials that are in development.
4 CID 1997; 24 (Suppl 1) Enterococcal Resistance to Antibiotics S83 For instance, a combination of streptogramin A and B antibiotics (quinupristin/dalfopristin) has been used for treatment of severe infections due to multidrug-resistant strains of E. faecium. Unfortunately, a strain that produces an acetyltransferase modifying the streptogramin A component of the combination has already been described [45]. The facility of enterococci at acquiring new resistance determinants is extended to antibiotics that are not used to treat enterococcal infections because of their weak activity against these organisms. Most strains are also resistant to tetracyclines (via tetk, tetl, tetm, and teto genes), macrolides (via erm genes), and chloramphenicol (via cat genes). In addition, numerous strains of E. faecalis highly resistant to gentamicin are resistant to ciprofloxacin. Although of slight clinical significance, these resistances are not harmless, since resistant enterococci might be selected by antibiotics not used against these bacteria. Conclusion Evolution of enterococci toward resistance to multiple antimicrobials is a major cause of concern. The fact that these organisms are less virulent than others is not reassuring, since acquisition by the bacteria of virulence genes is possible. Enterococci constitute a large reservoir of resistance genes, and because they are ubiquitous, the spread of high-level vancomycin resistance in methicillin-resistant staphylococci is to be feared. References 1. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91(suppl 3B): 72S-5S. 2. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990; 3: Fontana R, Cerini R, Longoni P, Grossato A, Canepari P. Identification of a streptococcal penicillin-binding protein that reacts very slowly with penicillin. J Bacteriol 1983; 155: Williamson R, Le Bouguenec C, Gutmann L, Horaud T. One or two lowaffinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin. J Gen Microbiol 1985; 131: Bryan LE, Van Den Elzen HM. Effects of membrane-energy mutations and cations on streptomycin and gentamicin accumulation by bacteria: a model for entry of streptomycin and gentamicin in susceptible and resistant bacteria. Antimicrob Agents Chemother 1977;12: Moellering RC Jr, Weinberg AN. Studies on antibiotic synergism against enterococci. II. Effect of various antibiotics on the uptake of "C-labeled streptomycin by enterococci. J Clin Invest 1971; 50: Hamilton-Miller JMT, Purves D. Enterococci and antifolate antibiotics. Eur J Clin Microbiol 1986; 5: Grayson ML, Thauvin-Eliopoulos C, Eliopoulos GM, et al. Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis. Antimicrob Agents Chemother 1990; 34: Costa Y, Galimand M, Leclercq R, Duval J, Courvalin P. Characterization of the chromosomal aac(6')-ii gene specific for Enterococcus faecium. Antimicrob Agents Chemother 1993; 37: Moellering RC Jr, Korzeniowski OM, Sande MA, Wennersten CB. Species-specific resistance to antimicrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis 1979; 140: Vincent S, Knight RG, Green M, Sahm DF, Shlaes DM. Vancomycin susceptibility and identification of motile enterococci. J Clin Microbiol 1991; 29: Leclercq R, Dutka-Malen S, Duval J, Courvalin P. Vancomycin resistance gene vanc is specific of Enterococcus gallinarum. Antimicrob Agents Chemother 1992;36: Navarro F, Courvalin P. Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens. Antimicrob Agents Chemother 1994; 38: Neu HC, Chin N, Gu J. The in-vitro activity of new streptogramins, RP 59500, RP and RP 54476, alone and in combination. J Antimicrob Chemother 1992; 30(suppl A): Murray BE. f3-lactamase-producing enterococci. Antimicrob Agents Chemother 1992; 36: Zscheck KK, Murray BE. Nucleotide sequence of the 0-lactamase gene from Enterococcus faecalis HH22 and its similarity to staphylococcal,q-lactamase genes. Antimicrob Agents Chemother 1991;35: Smith MC, Murray BE. Sequence analysis of the 0-lactamase repressor from Staphylococcus aureus and hybridization studies with two 0-lactamase-producing isolates of Enterococcus faecalis. Antimicrob Agents Chemother 1992; 36: Murray BE, Singh KV, Markowitz SM, et al. Evidence for clonal spread of a single strain of 0-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J Infect Dis 1991; 163: Fontana R, Grossato A, Rossi L, Cheng YR, Satta G. Transition from resistance to hypersusceptibility to 0-lactam antibiotics associated with loss of a low-affinity penicillin-binding protein in a Streptococcus faecium mutant highly resistant to penicillins. Antimicrob Agents Chemother 1985;28: Ligozzi M, Pittaluga F, Fontana R. Identification of a genetic element (psr) which negatively controls expression of Enterococcus hirae penicillinbinding protein 5. J Bacteriol 1993;175: El Kharroubi A, Jacques P, Piras G, Van Beeumen J, Coyette J, Ghuysen J-M. The Enterococcus hirae R40 penicillin-binding protein 5 and the methicillin-resistant Staphylococcus aureus penicillin-binding protein 2' are similar. Biochem J 1991;280: Al-Obeid S, Gutmann L, Williamson R. Modification of penicillin-binding proteins of penicillin-resistant mutants of different species of enterococci. J Antimicrob Chemother 1990;26: Fontana R, Aldegheri M, Ligozzi M, Lopez H, Sucari A, Satta G. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1994;38: Courvalin P, Carlier C, Collatz E. Plasmid-mediated resistance to aminocyclitol antibiotics in group D streptococci. J Bacteriol 1980; 143: Eliopoulos GM, Farber BF, Murray BE, Wennersten C, Moellering RC Jr. Ribosomal resistance of clinical enterococcal isolates to streptomycin. Antimicrob Agents Chemother 1984;25: Courvalin P, Carlier C, Collatz E. Structural and functional relationships between aminoglycoside-modifying enzymes from streptococci and staphylococci. In: Mitsuhashi S, Rosival L, Kremery V, eds. Medical and biological aspects of resistant strains. Berlin: Springer-Verlag, 1980: Leclercq R, Dutka-Malen S, Brisson-Noël A, et al. Resistance of enterococci to aminoglycosides and glycopeptides. Clin Infect Dis 1992; 15: Hoffmann SA, Moellering RC Jr. The enterococcus: "putting the bug in our ears." Ann Intern Med 1982; 106: Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin resistant enterococci [letter]. Lancet 1988; 1:57-8.
5 S84 Leclercq CID 1997; 24 (Suppi 1) 30. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319: Quintiliani R Jr, Evers S, Courvalin P. The vanb gene confers various levels of self-transferable resistance to vancomycin in enterococci. J Infect Dis 1993; 167: Quintiliani R Jr, Courvalin P. Conjugal transfer of the vancomycin resistance determinant vanb between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol Letters 1994; 119: Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993; 37: Arthur M, Molinas C, Depardieu F, Courvalin P. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 1993; 175: Barna JCJ, Williams DH. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol 1984; 38: Bugg TDH, Wright GD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 1991; 30: Reynolds PE, Depardieu F, Dutka-Malen S, Arthur M, Courvalin P. Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of vanx for hydrolysis of D-alanyl-D-alanine. Mol Microbiol 1994; 13: Arthur M, Molinas C, Courvalin P. Sequence of the vany gene required for production of a vancomycin-inducible D,D-carboxypeptidase in Enterococcus faecium BM4147. Gene 1992; 120: Arthur M, Depardieu F, Molinas C, Reynolds P, Courvalin P. The vanz gene of Tn1546 from Enterococcus faecium BM4147 confers resistance to teicoplanin. Gene 1995; 154: Arthur M, Molinas C, Courvalin P. The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 1992; 174: Leclercq R, Derlot E, Weber M, Duval J, Courvalin P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1989; 33: Engel HWB, Soedirman N, Rost JA, van Leeuwen WJ, van Embden JDA. Transferability of macrolide, lincomycin, and streptogramin resistances between group A, B, and D streptococci, Streptococcus pneumoniae, and Staphylococcus aureus. J Bacteriol 1980; 142: Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC to Staphylococcus aureus. FEMS Microbiol Lett 1992; 93: Bates J, Jordens JZ, Griffiths DT. Farm animals as a putative reservoir for vancomycin-resistant enterococcal infections in man. J Antimicrob Chemother 1994; 34: Rende-Fournier R, Leclercq R, Galimand M, Duval J, Courvalin P. Identification of the sata gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145. Antimicrob Agents Chemother 1993; 37:
Consequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationEvolution of antibiotic resistance. October 10, 2005
Evolution of antibiotic resistance October 10, 2005 Causes of death, 2001: USA 6. Population: 6,122,210,000 Deaths: 56,554,000 1. Infectious and parasitic diseases: 14.9 million 1. 2. 3. 4. 5. 2. Heart
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationResistance to Glycopeptides in Enterococci
545 STATE-OF-THE-ART CLINICAL ARTICLE Resistance to Glycopeptides in Enterococci Roland Leclercq and Patrice Courvalin The development of resistance to glycopeptides (vancomycin and teicoplanin) is one
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationCombating antibiotic resistance. October 23, 2006
Combating antibiotic resistance October 23, 2006 Causes of death, 2001: USA 6. Population: 6,122,210,000 Deaths: 56,554,000 1. Infectious and parasitic diseases: 14.9 million 1. 2. 3. 4. 5. 2. Heart diseases:
More informationAntibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationESCMID Online Lecture Library. by author
ESCMID Postgraduate Technical Workshop Antimicrobial susceptibility testing and surveillance of resistance in Gram-positive cocci: laboratory to clinic Current epidemiology of invasive enterococci in Europe
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationAntimicrobial Resistance and Prescribing
Antimicrobial Resistance and Prescribing John Ferguson, Microbiology & Infectious Diseases, John Hunter Hospital, University of Newcastle, NSW, Australia M Med Part 1 updates UPNG 2017 Tw @mdjkf http://idmic.net
More informationIntroduction to antimicrobial agents
Introduction to antimicrobial agents Kwan Soo Ko Action mechanisms of antimicrobials Bacteriostatic agents, such as tetracycline - Inhibit the growth and multiplication of bacteria - Upon exposure to a
More informationAntimicrobial Resistance in the Intensive Care Unit: Mechanisms, Epidemiology, and Management of Specific Resistant Pathogens
Antimicrobial Resistance in the Intensive Care Unit: Mechanisms, Epidemiology, and Management of Specific Resistant Pathogens Henry S. Fraimow, MD a, *, Constantine Tsigrelis, MD b KEYWORDS Resistance
More informationAntibiotic Resistance in Bacteria
Antibiotic Resistance in Bacteria Electron Micrograph of E. Coli Diseases Caused by Bacteria 1928 1 2 Fleming 3 discovers penicillin the first antibiotic. Some Clinically Important Antibiotics Antibiotic
More informationWHY IS THIS IMPORTANT?
CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationCombating antibiotic resistance
Combating antibiotic resistance October 8, 2007 Causes of death, 2001: USA 6. Population: 6,122,210,000 Deaths: 56,554,000 1. Infectious and parasitic diseases: 14.9 million 1. 2. 3. 4. 5. 2. Heart diseases:
More informationAntimicrobials & Resistance
Antimicrobials & Resistance History 1908, Paul Ehrlich - Arsenic compound Arsphenamine 1929, Alexander Fleming - Discovery of Penicillin 1935, Gerhard Domag - Discovery of the red dye Prontosil (sulfonamide)
More informationChapter 2 Mechanisms of Antimicrobial Resistance
Chapter 2 Mechanisms of Antimicrobial Resistance Denis K. Byarugaba Abstract There is no doubt that antimicrobial agents have saved the human race from a lot of suffering due to infectious disease burden.
More informationANTIMICROBIAL SUSCEPTIBILITY VANCOMYCIN RESISTANCE IN AN UNCOMMON ENTEROCOCCAL SPECIES
ENTEROCOCCAL SPECIES Sample ES-02 was a simulated blood culture isolate from a patient with symptoms of sepsis. Participants were asked to identify any potential pathogen and to perform susceptibility
More informationAntibiotics & Resistance
What are antibiotics? Antibiotics & esistance Antibiotics are molecules that stop bacteria from growing or kill them Antibiotics, agents against life - either natural or synthetic chemicals - designed
More informationnumber Done by Corrected by Doctor Dr Hamed Al-Zoubi
number 8 Done by Corrected by Doctor Dr Hamed Al-Zoubi 25 10/10/2017 Antibacterial therapy 2 د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy Figure 2/ Antibiotics target Inhibition of microbial
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationGlobal Alliance for Infections in Surgery. Better understanding of the mechanisms of antibiotic resistance
Better understanding of the mechanisms of antibiotic resistance Antibiotic prescribing practices in surgery Contents Mechanisms of antibiotic resistance 4 Antibiotic resistance in Enterobacteriaceae 9
More informationAntimicrobial agents
Bacteriology Antimicrobial agents Learning Outcomes: At the end of this lecture, the students should be able to: Identify mechanisms of action of antimicrobial Drugs Know and understand key concepts about
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationSUPPLEMENT ARTICLE. Donald E. Low, 1 Nathan Keller, 2 Alfonso Barth, 3 and Ronald N. Jones 4
SUPPLEMENT ARTICLE Clinical Prevalence, Antimicrobial Susceptibility, and Geographic Resistance Patterns of Enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997 1999 Donald E.
More informationMicrobiology ( Bacteriology) sheet # 7
Microbiology ( Bacteriology) sheet # 7 Revision of last lecture : Each type of antimicrobial drug normally targets a specific structure or component of the bacterial cell eg:( cell wall, cell membrane,
More informationEmergence of Vancomycin-Resistant Enterococci
Emergence of Vancomycin-Resistant Enterococci Louis B. Rice VA Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA Vancomycin and ampicillin resistance in clinical
More informationInhibiting Microbial Growth in vivo. CLS 212: Medical Microbiology Zeina Alkudmani
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology Zeina Alkudmani Chemotherapy Definitions The use of any chemical (drug) to treat any disease or condition. Chemotherapeutic Agent Any drug
More informationEnterococcal infections & antimicrobial resistance
Review Article Indian J Med Res 128, August 2008, pp 111-121 Enterococcal infections & antimicrobial resistance Seema Sood, Meenakshi Malhotra, B.K. Das & Arti Kapil Department of Microbiology, All India
More informationENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN
ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST
More informationWhat is multidrug resistance?
What is multidrug resistance? Umaer Naseer Senior Research Scientist Department of Zoonotic, Water- and Foodborne Infections Norwegian Institute of Public Health Magiorakos A.P. et al 2012 Definition of
More informationAn#bio#cs and challenges in the wake of superbugs
An#bio#cs and challenges in the wake of superbugs www.biochemj.org/bj/330/0581/bj3300581.htm ciss.blog.olemiss.edu Dr. Vassie Ware Bioscience in the 21 st Century November 14, 2014 Who said this and what
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationAntibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut
Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance
More informationMINIREVIEW. VanA-Type Vancomycin-Resistant Staphylococcus aureus. Bruno Périchon and Patrice Courvalin*
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2009, p. 4580 4587 Vol. 53, No. 11 0066-4804/09/$12.00 doi:10.1128/aac.00346-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. MINIREVIEW
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationβ-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa March 2018
β-lactams resistance among Enterobacteriaceae in Morocco 1 st ICREID Addis Ababa 12-14 March 2018 Antibiotic resistance center Institut Pasteur du Maroc Enterobacteriaceae (E. coli, Salmonella, ) S. aureus
More informationMechanisms and Pathways of AMR in the environment
FMM/RAS/298: Strengthening capacities, policies and national action plans on prudent and responsible use of antimicrobials in fisheries Final Workshop in cooperation with AVA Singapore and INFOFISH 12-14
More informationProject Summary. Impact of Feeding Neomycin on the Emergence of Antibiotic Resistance in E. coli O157:H7 and Commensal Organisms
Project Summary Impact of Feeding Neomycin on the Emergence of Antibiotic Resistance in E. coli O157:H7 and Commensal Organisms Principal Investigators: Mindy Brashears, Ph.D., Texas Tech University Guy
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationAntimicrobial Therapy
Chapter 12 The Elements of Chemotherapy Topics - Antimicrobial Therapy - Selective Toxicity - Survey of Antimicrobial Drug - Microbial Drug Resistance - Drug and Host Interaction Antimicrobial Therapy
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationAs antibiotic use increases in veterinary medicine, the issue of bacterial resistance
464 V Vol. 23, No. 5 May 2001 Email comments/questions to compendium@medimedia.com CE Article #5 (1.5 contact hours) Refereed Peer Review KEY FACTS Bacteria become resistant to antibiotics following a
More informationAntibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi
Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What
More informationTRANSFERABLE RESISTANCE AND AMINOGLYCOSIDE-MODIFYING ENZYMES IN ENTEROCOCCI
J. MED. MICROBIOL. VOL.-20 (1985) 187-196 0 1985 The Pathological Society of Great Britain and Ireland TRANSFERABLE RESISTANCE AND AMINOGLYCOSIDE-MODIFYING ENZYMES IN ENTEROCOCCI H. Y. CHEN* AND J. D.
More informationCell Wall Inhibitors. Assistant Professor Naza M. Ali. Lec 3 7 Nov 2017
Cell Wall Inhibitors Assistant Professor Naza M. Ali Lec 3 7 Nov 2017 Cell wall The cell wall is a rigid outer layer, it completely surrounds the cytoplasmic membrane, maintaining the shape of the cell
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationIntroduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018
Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.
More informationGlycopeptide Resistant Enterococci (GRE) Policy IC/292/10
BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,
More informationAntibiotic resistance a mechanistic overview Neil Woodford
Antibiotic Resistance a Mechanistic verview BSc PhD FRCPath Consultant Clinical Scientist 1 Polymyxin Colistin Daptomycin Mechanisms of antibiotic action Quinolones Mupirocin Nitrofurans Nitroimidazoles
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationAgent-Resistant Enterococci
JOURNAL OF CLINICAL MICROBIOLOGY, July 1993, p. 1695-1699 0095-1137/93/071695-05$02.00/0 Copyright 1993, American Society for Microbiology Vol. 31, No. 7 Ability of Clinical Laboratories To Detect Antimicrobial
More informationIn vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative
Journal of Antimicrobial Chemotherapy (2008) 62, 116 121 doi:10.1093/jac/dkn124 Advance Access publication 19 April 2008 In vitro activity of telavancin against recent Gram-positive clinical isolates:
More informationANTIBIOTIC RESISTANCE. Syed Ziaur Rahman, MD, PhD D/O Pharmacology, JNMC, AMU, Aligarh
ANTIBIOTIC RESISTANCE Syed Ziaur Rahman, MD, PhD D/O Pharmacology, JNMC, AMU, Aligarh WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development
More informationEUCAST Expert Rules for Staphylococcus spp IF resistant to isoxazolylpenicillins
EUAST Expert Rules for 2018 Organisms Agents tested Agents affected Rule aureus Oxacillin efoxitin (disk diffusion), detection of meca or mec gene or of PBP2a All β-lactams except those specifically licensed
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationGlycopeptide Resistance in Gram-positive Bacteria
~ CONTINUING EDUCATION Glycopeptide Resistance in Gram-positive Bacteria David C.E. Speller, William A. Lynn+ and Thomas R. Rogers* Readers are invited to use this article as a self-assessment exercise
More informationDalbavancin, enterococci, Gram-positive cocci, Latin America, staphylococci, streptococci
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01051.x Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres A. C. Gales 1, H. S. Sader 1,2
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationSynergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci
Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious
More informationAntimicrobial agents. are chemicals active against microorganisms
Antimicrobial agents are chemicals active against microorganisms Antibacterial Agents Are chemicals active against bacteria Antimicrobials Antibacterial Antifungal Antiviral Antiparasitic: -anti protozoan
More informationAntimicrobial Resistance Strains
Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More information10/15/08. Activity of an Antibiotic. Affinity for target. Permeability properties (ability to get to the target)
Beta-lactam antibiotics Penicillins Target - Cell wall - interfere with cross linking Actively growing cells Bind to Penicillin Binding Proteins Enzymes involved in cell wall synthesis Activity of an Antibiotic
More informationEUCAST expert rules in antimicrobial susceptibility testing
REVIEW BACTERIOLOGY EUCAST expert rules in antimicrobial susceptibility testing R. Leclercq 1,2, R. Cantón 2,3,4, D. F. J. Brown 4, C. G. Giske 2,4,5, P. Heisig 2,6, A. P. MacGowan 4,7, J. W. Mouton 4,8,
More informationFrank Møller Aarestrup
Danish Veterinary Laboratory Bacterial populations and resistance development: Intestinal tract of meat animals Frank Møller Aarestrup 12 Antibiotic production 10 Mill. Kg 8 6 4 2 0 50 52 54 56 58 60 62
More informationANTIMICROBIAL SUSCEPTIBILITY CONTEMPORARY SUSCEPTIBILITY TESTS AND TREATMENTS FOR VRE INFECTIONS
TREATMENTS FOR VRE INFECTIONS Sample ES-01 (2015) was a simulated blood culture isolate from a patient with associated clinical symptoms (pure culture). Participants were requested to identify any potential
More informationChapter concepts: What are antibiotics, the different types, and how do they work? Antibiotics
Chapter concepts: Antibiotics What are antibiotics, the different types, and how do they work? How do we decided on the most appropriate antibiotic treatment? What are some of the ways that bacteria are
More informationIntroduction to Antimicrobials. Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail.
Introduction to Antimicrobials Rachel J. Gordon, MD, MPH Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail. Major Learning Objectives: 1) Learn the different
More informationSusceptibility Testing of Clinical Isolates of Enterococcus faecium
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1992, p. 41-45 0095-1137/92/010041-05$02.00/0 Copyright 1992, American Society for Microbiology Vol. 30, No. 1 Susceptibility Testing of Clinical Isolates of Enterococcus
More informationTERMS OF REFERENCE (June 1997, Reviewed 17/9/97) BACKGROUND. (opinion expressed on 05 February 1998)
Report of the Scientific Committee for Animal Nutrition on the Efficacy and Risk for Users of the Therapeutic Macrolides Antibiotics Tylosin and Spiramycin Used as Feed Additives (opinion expressed on
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationManagement of Native Valve
Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis
More informationMRSA ST398 from swine and cattle
Novel antimicrobial resistance genes among livestock-associated MRSA ST398 from swine and cattle Kristina Kadlec, Andrea Feßler and Stefan Schwarz Institute of Farm Animal Genetics,, Friedrich-Loeffler
More informationInt.J.Curr.Microbiol.App.Sci (2018) 7(8):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 08 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.708.378
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationOrigins of Resistance and Resistance Transfer: Food-Producing Animals.
Origins of Resistance and Resistance Transfer: Food-Producing Animals. Chris Teale, AHVLA. Origins of Resistance. Mutation Brachyspira hyodysenteriae and macrolide and pleuromutilin resistance. Campylobacter
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationAminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.
Aminoglycosides The only bactericidal protein synthesis inhibitors. They bind to the ribosomal 30S subunit. Inhibit initiation of peptide synthesis and cause misreading of the genetic code. Streptomycin
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationAntimicrobial Activity of Linezolid Against Gram-Positive Cocci Isolated in Brazil
BJID 2001; 5 (August) 171 Antimicrobial Activity of Linezolid Against Gram-Positive Cocci Isolated in Brazil Helio S. Sader, Ana C. Gales and Ronald N. Jones Special Clinical Microbiology Laboratory, Division
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationOver the past several decades, the frequency of. Resistance Patterns Among Nosocomial Pathogens* Trends Over the Past Few Years. Ronald N.
Resistance Patterns Among Nosocomial Pathogens* Trends Over the Past Few Years Ronald N. Jones, MD Multiple surveillance studies have demonstrated that resistance among prevalent pathogens is increasing
More informationAn Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus
Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding
More informationAntimicrobial use in poultry: Emerging public health problem
Antimicrobial use in poultry: Emerging public health problem Eric S. Mitema, BVM, MS, PhD CPD- Diagnosis and Treatment of Poultry Diseases FVM, CAVS, 6 th. August, 2014 AMR cont Antibiotics - Natural or
More informationAntibiotic Combinations: Should They Be Tested?
CLINICAL MICROBIOLOGY REVIEWS, Apr. 1988, p. 139-156 Vol. 1, No. 2 0893-8512/88/020139-18$02.00/0 Copyright 1988, American Society for Microbiology Antibiotic Combinations: Should They Be Tested? G. M.
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More information